Loading…
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $14M | $-25M | $-25M | $-23M | -190.9% | 15.3% | - |
| 2024 | $12M | $-19M | $-20M | $-20M | 15.4% | 20.5% | - |
| 2023 | $10M | $-11M | $-11M | $-12M | 10.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Revenue | 9.75 | 11.76 | 13.55 |
| Cost Of Revenue | 4.26 | 5.38 | 6.38 |
| Gross Profit | 5.49 | 6.38 | 7.17 |
| Operating Expense | 16.84 | 26.29 | 32.69 |
| Operating Income | -11.35 | -19.92 | -25.52 |
| EBITDA | -10.96 | -19.40 | -24.95 |
| EBIT | -11.35 | -19.92 | -25.52 |
| Pretax Income | -11.29 | -19.89 | -25.29 |
| Tax Provision | 0.01 | 0.01 | 0.02 |
| Net Income | -11.30 | -19.90 | -25.32 |
| Net Income Common Stockholders | -11.30 | -19.90 | -25.32 |
| Total Expenses | 21.10 | 31.67 | 39.07 |
| Interest Income | 0.05 | 0.03 | 0.27 |
| Research And Development | 9.33 | 15.12 | 18.31 |
| Selling General And Administration | 7.50 | 11.17 | 14.38 |
| Normalized EBITDA | -10.96 | -19.40 | -24.95 |
| Normalized Income | -11.30 | -19.90 | -25.32 |
| Basic EPS | -0.29 | -0.43 | 0 |
| Diluted EPS | -0.29 | -0.43 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -11.30 | -19.90 | -25.32 |
| Reconciled Depreciation | 0.39 | 0.52 | 0.57 |
| Reconciled Cost Of Revenue | 4.26 | 5.38 | 6.38 |
| Net Interest Income | 0.05 | 0.03 | 0.27 |
| Net Income From Continuing And Discontinued Operation | -11.30 | -19.90 | -25.32 |
| Total Operating Income As Reported | -11.35 | -19.92 | -25.52 |
| Diluted Average Shares | 38.62 | 46.34 | 0 |
| Basic Average Shares | 38.62 | 46.34 | 0 |
| Diluted NI Availto Com Stockholders | -11.30 | -19.90 | -25.32 |
| Net Income Including Noncontrolling Interests | -11.30 | -19.90 | -25.32 |
| Net Income Continuous Operations | -11.30 | -19.90 | -25.32 |
| Other Income Expense | 0 | 0 | -0.04 |
| Other Non Operating Income Expenses | 0 | 0 | -0.04 |
| Net Non Operating Interest Income Expense | 0.05 | 0.03 | 0.27 |
| Interest Income Non Operating | 0.05 | 0.03 | 0.27 |
| Selling And Marketing Expense | 5.53 | 6.97 | 7.53 |
| General And Administrative Expense | 1.97 | 4.21 | 6.85 |
| Other Gand A | 1.97 | 4.21 | 6.85 |
| Operating Revenue | 9.75 | 11.76 | 13.55 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CapsoVision, Inc.this co. | CV | $319M | - | 22.61 | -190.9% | -12.32 |
| Evolus, Inc. | EOLS | $337M | - | -14.59 | 223.5% | -14.56 |
| Monopar Therapeutics Inc. | MNPR | $335M | - | 2.43 | -10.0% | - |
| Cross Country Healthcare, Inc. | CCRN | $331M | - | 1.01 | -29.4% | 12.17 |
| SIGA Technologies, Inc. | SIGA | $325M | 14.16 |
| 1.63 |
| 11.7% |
| 7.02 |
| DiaMedica Therapeutics Inc. | DMAC | $321M | - | 5.71 | -58.4% | -7.61 |
| ClearPoint Neuro, Inc. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| Anavex Life Sciences Corp. | AVXL | $302M | - | 2.39 | -48.9% | - |
| Compass Therapeutics, Inc. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| Peer Median | - | 14.16 | 2.01 | -31.6% | -4.51 | |